Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Seclidemstat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Clinical Data On Salarius’ Seclidemstat In MDS And CMML Presented At EHA 2024
    Clinical Data On Salarius’ Seclidemstat In MDS And CMML Presented At EHA 2024

    17 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/17/2899601/0/en/Clinical-Data-on-Salarius-Pharmaceuticals-Seclidemstat-in-Patients-with-MDS-and-CMML-Presented-at-the-2024-European-Hematology-Association-Annual-Meeting.html

    GLOBENEWSWIRE
    17 Jun 2024
    Share Share
    Salarius Provides Update on Review Process to Support Seclidemstat Trials
    Salarius Provides Update on Review Process to Support Seclidemstat Trials

    22 Feb 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/02/22/2833642/0/en/Salarius-Provides-Update-on-Strategic-Review-Process-and-Plans-to-Support-Ongoing-Seclidemstat-Clinical-Trials-by-Further-Reducing-Expenses.html

    GLOBENEWSWIRE
    22 Feb 2024
    Share Share
    Investigator-initiated Phase 1/2 Clinical Trial Using Salarius' Seclidemstat to Treat Hematologic Cancers
    Investigator-initiated Phase 1/2 Clinical Trial Using Salarius' Seclidemstat to Treat Hematologic Cancers

    03 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/01/03/2803302/0/en/Investigator-initiated-Phase-1-2-Clinical-Trial-Using-Salarius-Pharmaceuticals-Seclidemstat-in-Combination-with-Azacitidine-to-Treat-Hematologic-Cancers-Resumes-Patient-Enrollment.html

    GLOBENEWSWIRE
    03 Jan 2024
    Share Share
    Salarius Completes FDA Meeting for Seclidemstat Sarcoma Development Program
    Salarius Completes FDA Meeting for Seclidemstat Sarcoma Development Program

    07 Nov 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/11/07/2775117/0/en/Salarius-Completes-FDA-Type-B-Meeting-for-Seclidemstat-Ewing-Sarcoma-Development-Program.html

    GLOBENEWSWIRE
    07 Nov 2023
    Share Share
    FDA frees Salarius’ rare cancer asset from clinical hold
    FDA frees Salarius’ rare cancer asset from clinical hold

    10 May 2023

    // Gabrielle Masson FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/salarius-breaks-free-fda-hold-rare-cancer-trial-after-patient-death

    Gabrielle Masson FIERCE BIOTECH
    10 May 2023
    Share Share
    Salarius to Present In Vitro Data on Seclidemstat in Small Cell Lung Cancer
    Salarius to Present In Vitro Data on Seclidemstat in Small Cell Lung Cancer

    07 Mar 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/03/07/2621987/0/en/Salarius-Pharmaceuticals-to-Present-In-Vitro-Data-on-Seclidemstat-in-Small-Cell-Lung-Cancer-at-the-Keystone-Symposia.html

    GLOBENEWSWIRE
    07 Mar 2023
    Share Share